-
Mashup Score: 3Unveiling the Molecular Hallmarks of Peyronie's Disease: A Comprehensive Narrative Review - Beyond the Abstract - 1 hour(s) ago
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone, SMAD3 phosphorylation inhibitor, fresolimumab, monoclonal antibody, inhibiting all TGF isoforms, fibroblast activation protein (FAP)-targeted chimeric antigen receptor T (CAR-T) cells, FAP-targeted CAR T-cell therapy.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3
Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness. #AuthorCommentary on UroToday > https://t.co/L7tMYN7H10 @Mehdi_Kardoust @AdityaBagrodia @kensuke_bekku @DrShariat… https://t.co/F2hRHFcWTv https://t.co/aOcpoCyWOb
-
-
Mashup Score: 19
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom Score (AUASS), overactive bladder symptom score (OABSS).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing holmium laser enucleation of the prostate outcomes reporting: an assessment of patient-reported outcomes in the literature. #AuthorCommentary from @laenahines @URMCUrology. #ReadNow on UroToday > https://t.co/HVN3SeWT6j @urogoldjournal https://t.co/dXaijRjs8q
-
-
Mashup Score: 10
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor dosimetry in PSMA therapy: A #VISION substudy analysis. @ProfKHerrmann joins Oliver Sartor, MD discussing tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in #ProstateCancer patients. #FullVideo on UroToday > https://t.co/igHM3XAkST https://t.co/eHnyrkT4Ie
-
-
Mashup Score: 2
Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Study highlights the efficacy of MRI-compatible sacral nerve stimulators in managing fecal incontinence. Results from a multi-institutional analysis show promising outcomes for safety and quality of life. Explore the findings here > https://t.co/1bCQfqrX9d https://t.co/1A83eh8etj
-
-
Mashup Score: 0Sign up - 3 day(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Excited for #AUA25? Stay ahead with the latest updates, research, and highlights from the event! 🩺✨ Don't miss out on crucial insights—sign up for our exclusive newsletter coverage today and #FollowUs on #SoMe for updates throughout the conference! https://t.co/GN17FCaIS6 https://t.co/6ypiqLfpWz
-
-
Mashup Score: 5ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed - 4 day(s) ago
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current evidence establishes ctDNA detection as strongly prognostic at multiple timepoints, with detectable ctDNA before neoadjuvant therapy, after neoadjuvant therapy, or post-surgery consistently indicating poor outcomes. She…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
ctDNA as a prognostic biomarker in #BladderCancer treatment decisions. @Nimira_A @UCalgary sits down with @UroDocAsh @MDAndersonNews to discuss the evolution of ctDNA in muscle-invasive bladder cancer management. #WatchNow > https://t.co/KmX7W8mjyI https://t.co/zuOsjnxL8U
-
-
Mashup Score: 9
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic #UrothelialCarcinoma: a single-center retrospective study from 2004 to 2021. Author commentary on UroToday > https://t.co/usSBcA9NVa @TapiaJC1 https://t.co/9T2XK32PWP
-
-
Mashup Score: 5Medicare Part D Changes Reduce Out-of-Pocket Costs for Prostate Cancer Patients - David Morris - 5 day(s) ago
Ruchika Talwar interviews David Morris about changes to Medicare Part D resulting from the Inflation Reduction Act. Dr. Morris discusses how these changes benefit prostate cancer patients and other Medicare recipients by reducing out-of-pocket expenses for prescription drugs. Key points include the introduction of a $2,000 annual out-of-pocket maximum cap, the option for cost smoothing to spread…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#Medicare Part D changes reduce out-of-pocket costs for #ProstateCancer patients. David Morris, MD, FACS @UA_Nashville sits with @RuchikaTalwarMD @VUMCurology to discuss changes to Medicare Part D resulting from the Inflation Reduction Act > https://t.co/G6iiLFfMLV https://t.co/L6fzA11Jgo
-
-
Mashup Score: 3
Benign Prostatic Enlargement (BPH), Ejaculation-Sparing Enucleation of the Prostate with Thulium Yag Laser (ES-ThuLEP), Thulium Fiber Laser (ES-ThuFLEPEjaculation-Sparing Enucleation of the Prostate with Thulium Yag Laser (ES-ThuLEP) Versus Thulium Fiber Laser (ES-ThuFLEP), Retrograde ejaculation remains a major limitation of BPH surgery, BPH surgery.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Ejaculation-sparing enucleation of the prostate with Thulium: Yag Laser (ES-ThuLEP) versus Thulium Fiber Laser (ES-ThuFLEP): Outcomes on sexual function. #AuthorCommentary from @Davide_Perri90. #ReadNow on UroToday > https://t.co/UXPjoXgkd0 @wjurol
-
New insights into #PeyroniesDisease! A comprehensive review explores the molecular hallmarks of fibrosis, highlighting key players like TGF-β, PDGF, and MMP/TIMP imbalance. Could antifibrotic therapies & CAR-T cells offer future breakthroughs? #ReadNow > https://t.co/Ed7A2nQaLc… https://t.co/V95QKHui0E